2 results match your criteria: "University of Health and Rehabilitation Sciences and Qingdao Central Hospital Medical Group[Affiliation]"
Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity.
Stem Cells Int
March 2024
Department of Neurosurgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences and Qingdao Central Hospital Medical Group, Qingdao, Shandong 266042, China.
Article Synopsis
- Gliomas are the most common type of brain tumors with high malignancy, fast recurrence, and high mortality rates, and current treatments have limited success.
- Shikonin, a compound from traditional Chinese medicine, has shown effectiveness against gliomas by inducing a type of cell death called necroptosis and reducing markers associated with cancer stem cells.
- The study explores how Shikonin impacts the proteasome activity and immune proteasome subunits in glioma cells, suggesting its potential as a new treatment option for dealing with these challenging tumors.
Knockdown the moyamoya disease susceptibility gene, RNF213, upregulates the expression of basic fibroblast growth factor and matrix metalloproteinase-9 in bone marrow derived mesenchymal stem cells.
Neurosurg Rev
May 2024
Department of Geriatric Neurology, Anti-Aging Monitoring Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, Shandong, 250021, P.R. China.
Moyamoya disease (MMD) is a chronic, progressive cerebrovascular occlusive disease. Ring finger protein 213 (RNF213) is a susceptibility gene of MMD. Previous studies have shown that the expression levels of angiogenic factors increase in MMD patients, but the relationship between the susceptibility gene RNF213 and these angiogenic mediators is still unclear.
View Article and Find Full Text PDF